Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Three kinase inhibitors dasatinib type I imatinib
2020-07-23

Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007, Hantschel et al., 2008). These tyrosine kinase inhibitors
-
The two isoforms LDH A and LDH B
2020-07-23

The two isoforms LDH-A and LDH-B catalyze the same reaction, conversion of pyruvate to lactate at the end of glycolysis. LDH-A is expressed in the liver. Humans with a hereditary deficiency of the A or B LDH isoforms are free of symptoms, except for muscle rigidity and myoglobinuria following strenu
-
br Conclusion The results of the present
2020-07-23

Conclusion The results of the present study demonstrate that cysteinyl leukotrienes LTC4, LTD4 and LTE4 cause moderate to marked whereas the dihydroxy leukotriene LTB4 causes small muscle contraction in the stomach in vitro. The LTD4-induced contraction is mediated by CysLT1 in fundus but by CysL
-
pyruvate dehydrogenase kinase inhibitor Introduction Cystein
2020-07-23

Introduction Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are 5-lipoxygenase pathway metabolites of arachidonic pyruvate dehydrogenase kinase inhibitor and deeply involved in bronchial asthma via activation of CysLT1 receptors [1], [2]. Specific CysLT1 receptor antagonists, including pran
-
Western blotting Western blotting was
2020-07-23

Western blotting: Western blotting was performed following the standard protocol as previously described [16]. All the images were collected using the Odyssey Fc imaging system (Li-COR Biosciences). In vitro kinase assays were performed on ∼1 μg of purified CDK5/p35 complex in 30 μL of kinase buffe
-
Cot MAP K is the
2020-07-23

Cot (MAP3K8) is the sole MAP3K that activates the MEK1/2-Erk1/2 following the activation of the TLR/IL-1 receptor superfamily as well as some receptors of the TNF receptor family [8], [9], [10] and mediates the production of chemokines and cytokines in different cell systems [reviewed in [11]]. Thus
-
PI K Akt eNOS signaling is long been known as
2020-07-23

PI3K-Akt-eNOS signaling is long been known as a cell survival pathway in cardiology [8]. Current study has shown that ginsenosides, which is demonstrated to exhibit cardioprotective effect in several aspects, prevented cardiac ischemia/reperfusion injury via upregulation of PI3K and phosphorylations
-
The role of ETB clearing
2020-07-23

The role of ETB clearing receptors has been studied in detail in endothelial cell–specific ETB knock-out mice. In these animals, clearance of an intravenous Autophagy Compound Library mg of labeled ET-1 was reduced significantly compared with wild-type controls. Importantly, functioning ETB were re
-
DNA Damage DNA Repair Library Altogether the results of this
2020-07-23

Altogether, the results of this study demonstrate that peripheral blockade of both ETA and ETB receptors reduces tumor-induced facial heat hyperalgesia and increased spontaneous grooming, without modifying ongoing nociception. It is possible to suggest that bosentan is acting upon both receptors pre
-
Downregulation of tumor suppressors is a major factor that l
2020-07-23

Downregulation of tumor suppressors is a major factor that leads to tumorigenesis. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a common tumor suppressor, the GSK180 of which is often downregulated or even absent in the majority of human cancers, functions as a phosphatase to deph
-
SIRT has deacetylated regulation on numerous nonhistone
2020-07-23

SIRT1 has deacetylated regulation on numerous nonhistone protein substrates [Atgs, Foxo1, Foxo3, PGC-1α, NF-kB, E2F1 and p53] (Conrad et al., 2016) to play a key role in protecting against cell stress. Therefore, the role of SIRT1 in fluorine-induced oxidative stress was explored. The results reveal
-
Adding MPA or NETA we found no
2020-07-22

Adding MPA or NETA we found no impact on the estradiol-induced downregulation of serum-stimulated endothelin synthesis in vitro [40]. Progesterone was also able to inhibit the angiotensin II-induced increase in endothelin production [41]. Several clinical studies on the effect of oral or transdermal
-
In contrast irinotecan has shown much less myelosuppression
2020-07-22

In contrast, irinotecan has shown much less myelosuppression and may be more active in Ewing sarcoma both alone and in combination with temozolamide. One phase II study of 13 heavily pretreated Ewing sarcoma patients demonstrated a response rate of 38% including 2 complete responses (Bisogno et al.,
-
Tailoring pharmacological treatment to the genetic
2020-07-22

Tailoring pharmacological treatment to the genetic background of a person can enhance therapeutic response (), increase compliance (), and decrease drug toxicity (, , ). Because cocaine addiction has a strong genetic basis, with the vulnerability to develop an addiction estimated to be as high as 72
-
br Conclusion New series of
2020-07-22

Conclusion New series of thiazolo[4,5-d]pyridazine and imidazo[2′,1′:2,3]thiazolo[4,5-d]pyridazine were designed and synthesized using thiazole as scaffold based on its previously observed activity as DHFR inhibitor. Compounds 13 and 43 (Fig. 9) proved to be the most active DHFR inhibitors with I
15844 records 791/1057 page Previous Next First page 上5页 791792793794795 下5页 Last page